查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950438

C1-INH替代療法市場按產品類型、適應症、給藥途徑、最終用戶和分銷管道分類，全球預測，2026-2032年

C1-INH Replacement Therapy Market by Product Type, Indication, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，C1-INH 替代療法市場價值將達到 14.5 億美元，到 2026 年將成長至 16.4 億美元，到 2032 年將達到 35.2 億美元，複合年成長率為 13.50%。

關鍵市場統計數據
基準年 2025 14.5億美元
預計年份：2026年 16.4億美元
預測年份 2032 35.2億美元
複合年成長率 (%) 13.50%

影響 C1-INH 替代療法市場的臨床因素、治療方法和運作實際情況的權威概述

C1-INH替代療法在罕見疾病醫學和精準臨床管理領域佔據著至關重要的地位，其實證依據基於遺傳性和後天性補體路徑失調。因C1阻礙要素缺乏而發生血管性水腫的患者面臨潛在的危及生命的急性發作，需要定期預防策略和及時干預。該療法涵蓋血漿來源和重組產品，每種產品都體現了不同的生產模式、安全性考慮和給藥方法，這些因素都會影響臨床應用和治療路徑。

技術創新、不斷變化的法規和醫療服務模式正在重新定義 C1-INH 療法的臨床應用、安全預期和推廣動態。

受技術進步、法規演變和醫療服務模式變革的推動，C1-INH療法領域經歷了變革性轉變。血漿處理技術的進步，包括奈米過濾和檢驗的病原體減少技術，提高了血漿衍生產品的安全性。同時，重組表達系統的創新提高了生物製藥生產的一致性和擴充性，並提供了可降低血漿依賴風險的替代供應模式。

2025年關稅調整及其對C1-INH療法採購、庫存計畫和持續取得的重組，將對營運和採購產生連鎖影響。

2025年的關稅和貿易政策變化給美國供應鏈中的製造商和經銷商帶來了複雜的阻力以及區域成本壓力。關稅調整影響了原料和成品生物製藥的進口經濟效益，尤其是從國際供應商採購的血漿衍生成分和特殊試劑。因此，籌資策略進行了調整，以降低跨境價格波動帶來的風險，並維持關鍵治療藥物的持續供應。

一種深入的、以細分市場主導的觀點，揭示了產品類型、臨床適應症、給藥途徑、臨床環境和分銷管道如何驅動差異化的臨床和商業策略。

細分市場分析揭示了在評估產品類型、適應症、給藥途徑、最終用戶和分銷管道時，需求促進因素和臨床偏好路徑的細微差別。按產品類型分類，市場包括血漿來源的C1-INH和重組C1-INH。血漿來源的產品進一步細分為奈米過濾C1-INH和巴氏殺菌C1-INH，這會影響安全性認知、捐贈者依賴風險以及臨床醫生在做出處方決策時的舒適度。依適應症分類，產品分為急性治療和預防性治療，預防性治療進一步細分為長期預防性治療和短期預防性治療。這些區分決定了臨床試驗設計、真實世界證據的優先順序和患者選擇標準。

不同地區法規結構、醫療基礎設施和支付方環境的差異如何塑造個人化的醫療服務取得、商業化和病患支援路徑

區域趨勢將對美洲、歐洲、中東和非洲以及亞太地區的醫療服務取得、監管時間表和服務提供結構產生深遠影響。在美洲，臨床專家中心和先進的專科護理網路依然存在，這有助於推廣新型製劑和居家照護模式；同時，監管和報銷體系更加重視專科治療管理中的療效比較和基於價值的合約模式。

深入分析決定市場影響力和長期商業性永續性的競爭定位、產品差異化和策略發展。

C1-INH市場的競爭主要由傳統血漿衍生產品供應商和開發重組平台的生物技術公司共同推動，各方都力求透過安全性聲明、先進的給藥方案和服務體系來脫穎而出。成熟的血漿衍生產品生產商強調其長期安全性記錄、病原體減少技術和豐富的臨床經驗，因此更受重視成熟風險緩解方案的醫院處方集和專科醫生的青睞。同時，重組產品開發商則著重強調其擴充性生產、減少對捐贈者依賴和成本穩定性等潛在優勢，以吸引尋求供應來源多元化的支付方和採購部門。

製造商和相關人員需要製定明確的策略重點，以增強供應鏈韌性，加速居家醫療保健的普及，並根據可衡量的患者療效調整報銷機制。

產業領導者必須採取果斷行動，應對報銷壓力、供應鏈波動和不斷變化的臨床需求，同時推動以病人為中心的醫療服務。首先，應投資多元化的生產和採購策略，以降低受國際貿易波動的影響，並增強血漿衍生產品和籌資策略產品線的供應連續性。其次，應優先考慮皮下製劑和居家醫療支援工具的研發和監管申報，因為這些產品對患者的生活品質和依從性有顯著影響。

採用嚴謹的混合調查方法，結合臨床證據綜合、相關人員訪談和供應鏈分析，以產生可操作的策略洞見。

本研究整合了同行評審的臨床文獻、監管核准資訊、產品標籤和公司披露資訊，並結合對臨床醫生、支付方代表和供應鏈專家的初步定性訪談，全面展現了C1-INH治療領域的現狀。調查方法結合了從臨床試驗資料庫和安全性資料庫中系統提取證據，以及與專家進行有針對性的諮詢，以檢驗發展趨勢並解讀其對醫療服務運作的影響。

整合臨床、營運和商業性的必要因素將有助於實現C1-INH替代療法的持續可及性和以患者為中心的推廣應用。

C1-INH替代療法是一個充滿活力的治療領域，臨床創新、營運韌性和以患者為中心的護理模式共同決定著該領域的成功。產品類型的不斷發展，包括血漿衍生安全製程和重組生產技術的進步，在拓展治療選擇的同時，也帶來了藥物取得和採購的新考量。同時，皮下製劑和居家醫療模式的轉變正在重塑病患體驗和臨床工作流程，迫使相關人員重新評估培訓、報銷和支持基礎設施。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的 C1-INH 替代療法市場

  • 血漿來源的C1-INH
    • 奈米過濾C1-INH
    • 巴氏殺菌 C1-INH
  • 重組C1-INH

9. 依適應症分類的 C1-INH 替代療法市場

  • 急性治療
  • 預防
    • 長期預防性治療
    • 短期預防

10. 依給藥途徑分類的C1-INH替代療法市場

  • 靜脈注射
  • 皮下注射

第11章 以最終用戶分類的C1-INH替代療法市場

  • 居家醫療環境
  • 醫院
  • 專科診所

12. 按分銷管道分類的 C1-INH 替代療法市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 C1-INH替代療法市場：依地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 按組別分類的C1-INH替代療法市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國 C1-INH 替代療法市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 美國C1-INH替代療法市場

第17章 中國C1-INH替代療法市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AstraZeneca PLC
  • Biotest AG
  • CSL Behring GmbH
  • GlaxoSmithKline plc
  • Grifols SA
  • Kedrion SpA
  • LFB SA
  • Merck & Co. Inc.
  • Octapharma AG
  • Pfizer Inc.
  • Pharming Group NV
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4F7A6D4FD864

The C1-INH Replacement Therapy Market was valued at USD 1.45 billion in 2025 and is projected to grow to USD 1.64 billion in 2026, with a CAGR of 13.50%, reaching USD 3.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.45 billion
Estimated Year [2026] USD 1.64 billion
Forecast Year [2032] USD 3.52 billion
CAGR (%) 13.50%

An authoritative overview of clinical drivers, therapeutic modalities, and operational realities that define the C1-INH replacement therapy landscape

C1-INH replacement therapy occupies a critical niche at the intersection of rare disease therapeutics and precision clinical management, with an evidence base rooted in hereditary and acquired complement pathway dysregulation. Patients experiencing angioedema driven by C1 inhibitor deficiency face episodic, potentially life-threatening events that demand timely intervention and consistent prophylactic strategies. The therapeutic portfolio spans plasma-derived and engineered recombinant modalities, each reflecting distinct manufacturing paradigms, safety considerations, and delivery approaches that influence clinical adoption and care pathways.

Clinicians, payers, and health systems increasingly prioritize therapies that combine robust clinical efficacy with manageable administration profiles and clear safety margins. As a result, stakeholders evaluate products not only on biochemical potency but also on characteristics such as viral inactivation processes, subcutaneous formulations that support home administration, and stable supply chains that minimize treatment disruptions. Regulatory approvals and guideline endorsements play a pivotal role in shaping treatment algorithms, while patient advocacy and real-world outcome data continue to inform best practices and access strategies.

Together, these dynamics underscore the complexity and urgency surrounding C1-INH replacement therapy decisions. This introduction frames subsequent analysis by highlighting clinical drivers, product differentiation, and the operational realities that market participants must navigate to improve patient outcomes and sustain commercial viability.

How technological innovation, regulatory evolution, and care delivery shifts are redefining clinical use, safety expectations, and adoption dynamics for C1-INH therapies

The C1-INH landscape has undergone transformative shifts driven by technological progress, regulatory evolution, and changes in care delivery. Advances in plasma processing, including nanofiltration and validated pathogen-reduction techniques, have strengthened the safety profile of plasma-derived products. At the same time, innovations in recombinant expression systems have improved the consistency and scalability of biologic manufacturing, offering alternative supply models that can mitigate plasma-dependency risks.

Concurrently, regulatory frameworks have adapted to accommodate novel product attributes and alternative routes of administration. Approval pathways have increasingly recognized subcutaneous formulations as facilitators of home-based care, and guideline updates have integrated emerging evidence on long-term prophylaxis benefits for specific patient cohorts. These regulatory and clinical shifts have catalyzed broader adoption of self-administration practices, reshaping training requirements, patient education, and reimbursement discussions.

Market entry of new formulation types and incremental clinical data have also affected payer assessments and hospital formulary decisions. Value propositions now lean heavily on total-care considerations including reduced emergency interventions, improved quality-of-life metrics, and enhanced adherence potential. In turn, manufacturers focus on lifecycle evidence generation, patient support services, and differentiated supply chain reliability to secure preference among clinicians and care networks.

The cascading operational and procurement consequences of tariff shifts in 2025 and how they reshaped sourcing, inventory planning, and access continuity for C1-INH therapies

Policy changes affecting tariffs and trade in 2025 have created complex headwinds and localized cost pressures for manufacturers and distributors operating within the United States supply chain. Tariff adjustments have influenced the economics of importing raw materials and finished biologic products, particularly where plasma-derived components or specialized reagents are sourced from international suppliers. As a result, procurement strategies have adjusted to reduce exposure to cross-border pricing volatility and to preserve continuity of supply for critical therapies.

Manufacturers responded by revisiting sourcing footprints, increasing nearshoring of certain production activities, and renegotiating supplier contracts to incorporate tariff contingencies. These operational adaptations carry implications for production lead times, warehousing requirements, and inventory policies. Health systems and specialty pharmacies, in turn, evaluated their contracting terms and stocking protocols to anticipate potential cost shifts and to maintain availability for patients dependent on regular dosing regimens.

Importantly, tariff-driven cost pressures have accelerated stakeholder conversations around localized manufacturing investments and strategic partnerships that can insulate supply chains from future trade policy fluctuations. Payers and procurement teams have intensified scrutiny of total cost of care and of contractual levers that can stabilize patient access while preserving therapeutic continuity despite an evolving trade environment.

Deep segmentation-led perspective revealing how product type, clinical indication, administration routes, care settings, and distribution channels drive differentiated clinical and commercial strategies

Segmentation analysis reveals nuanced drivers of demand and routes to clinical preference when evaluated across product type, indication, route of administration, end user, and distribution channel. Based on product type, the market includes Plasma Derived C1-INH and Recombinant C1-INH, with plasma-derived offerings further differentiated by Nanofiltered C1-INH and Pasteurized C1-INH, which influence perceived safety, donor-dependency risks, and clinician comfort during prescribing decisions. Based on indication, products are assessed for Acute Treatment and Prophylaxis, with prophylactic use subdivided into Long Term Prophylaxis and Short Term Prophylaxis; these distinctions determine clinical trial designs, real-world evidence priorities, and patient selection criteria.

Based on route of administration, Intravenous and Subcutaneous options dictate care pathway design and patient education needs, with subcutaneous formulations facilitating homecare adoption and intravenous formulations often remaining hospital- or clinic-centered. Based on end user, care settings span Homecare Setting, Hospital, and Specialty Clinic, each carrying different operational requirements, training protocols, and reimbursement interactions. Based on distribution channel, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy models shape logistics, adherence support, and patient convenience.

By integrating these segmentation lenses, stakeholders can prioritize product development, commercial tactics, and service offerings that align with clinician workflows and patient preferences. For example, a recombinant subcutaneous option targeted at long-term prophylaxis for home-based administration will necessitate distinct training, adherence monitoring, and reimbursement positioning compared with a nanofiltered intravenous product optimized for acute inpatient management. These segmentation-driven insights support focused evidence generation, tailored payer engagement, and differentiated commercialization strategies.

How distinct regulatory frameworks, care infrastructures, and payer environments across major regions create tailored pathways for access, commercialization, and patient support

Regional dynamics profoundly influence access, regulatory timelines, and the structure of service delivery across the Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas continue to feature concentrated centers of clinical expertise and advanced specialty care networks that facilitate uptake of novel formulations and homecare models, while regulatory and reimbursement ecosystems emphasize comparative effectiveness and value-based contracting to manage specialty therapeutics.

In Europe, Middle East & Africa, variant national regulatory approaches and heterogeneous payer landscapes create diverse access pathways; some markets prioritize therapeutic guidelines and centralized reimbursement, whereas others require localized evidence and negotiation. In these regions, collaboration with regional clinical societies and local patient advocacy groups often accelerates guideline inclusion and formulary consideration. In the Asia-Pacific region, rapid healthcare infrastructure development and growing specialty pharmacy capabilities are increasing opportunities for early adoption, though market entry strategies must account for manufacturing approvals, local clinical practice patterns, and variable reimbursement criteria.

Across all regions, logistical considerations such as cold-chain integrity, plasma sourcing constraints, and distribution channel maturity shape the practicalities of delivering C1-INH therapies. Consequently, manufacturers and distributors tailor go-to-market plans to each region's regulatory cadence, clinical network density, and payer expectations, while investing in localized evidence generation and patient support programs to reduce barriers to access and optimize long-term adherence.

An incisive view of competitive positioning, product differentiation, and strategic maneuvers that determine market influence and long-term commercial resilience

Competitive dynamics in the C1-INH arena are driven by a mix of legacy plasma-derived suppliers and biotechnology companies developing recombinant platforms, each pursuing differentiation through safety assertions, administration advances, and service ecosystems. Established plasma-derived manufacturers emphasize long-term safety records, pathogen-reduction technologies, and extensive clinical experience, which resonate with hospital formularies and specialist prescribers that value proven risk mitigation practices. Conversely, recombinant product developers highlight manufacturing scalability, reduced donor dependency, and potential cost-stability benefits that appeal to payers and procurement teams seeking supply diversification.

Strategic maneuvers among industry participants include targeted clinical programs to support prophylactic indications, investments in subcutaneous delivery mechanisms to enable homecare adoption, and deployment of patient support and training services to improve adherence. Collaboration with specialty pharmacies, integrated delivery networks, and patient advocacy organizations remains central to building trust and facilitating real-world evidence generation. In parallel, portfolio strategies increasingly integrate lifecycle plans such as formulation improvements, pediatric-focused studies, and labeled expansions to secure long-term relevance in clinical pathways.

From a commercial perspective, differentiators extend beyond core product attributes to encompass supply-chain resilience, responsiveness to tariff and trade shifts, and the ability to provide comprehensive value-based contracting tools. These company-level strategies determine influence over prescribing patterns, access negotiations, and long-term positioning in patient-centric care models.

Clear strategic priorities for manufacturers and stakeholders to strengthen supply resilience, accelerate homecare adoption, and align reimbursement with measurable patient outcomes

Industry leaders must act decisively to navigate reimbursement pressures, supply-chain variability, and evolving clinical expectations while advancing patient-centered care. First, invest in diversified manufacturing and sourcing strategies that reduce exposure to international trade fluctuations and strengthen supply continuity for both plasma-derived and recombinant product lines. Second, prioritize development and regulatory submission pathways for subcutaneous formulations and homecare enablement tools, as these elements materially affect patient quality of life and adherence behaviors.

Simultaneously, commit to robust evidence generation that addresses prophylactic subpopulations, comparative safety across nanofiltration and pasteurization methods, and real-world outcomes tied to administration routes and care settings. Engage proactively with payers and hospital decision-makers to design outcomes-based agreements and bundled care models that align reimbursement with demonstrated reductions in acute care utilization. Additionally, expand patient support networks and digital adherence tools to lower barriers to self-administration and to capture longitudinal safety and efficacy data.

Finally, cultivate partnerships with specialty pharmacies, integrated delivery networks, and regional health authorities to accelerate guideline inclusion and streamline patient access. By operationalizing these recommendations, industry leaders can strengthen market differentiation, reduce systemic risks, and enhance the therapeutic experience for patients reliant on C1-INH replacement therapy.

A rigorous mixed-methods research approach combining clinical evidence synthesis, stakeholder interviews, and supply-chain analysis to produce actionable strategic insights

This research synthesized peer-reviewed clinical literature, regulatory approvals, product labels, company disclosures, and primary qualitative interviews with clinicians, payer representatives, and supply-chain specialists to construct a comprehensive view of the C1-INH landscape. The methodology combined systematic evidence abstraction from clinical trial registries and safety databases with targeted expert consultations to validate trends and interpret operational impacts on care delivery.

To ensure balanced insights, the approach triangulated clinical efficacy and safety data with stakeholder perspectives on formulary decision-making, distribution logistics, and patient support needs. Regional policy reviews and trade analyses informed evaluations of manufacturing footprint implications and procurement strategies in an evolving tariff environment. Throughout, methodological rigor emphasized transparency around sources, variant data interpretations, and areas where emerging evidence necessitates ongoing monitoring.

Limitations included variability in national reporting standards and heterogeneity of real-world evidence capture across care settings, which the research team addressed by weighting high-quality randomized data alongside consistent observational datasets and expert consensus. The combined methodology yields pragmatic conclusions designed to guide strategic decisions across product development, market access, and commercial operations.

Synthesis of clinical, operational, and commercial imperatives that together shape durable access and patient-centered adoption of C1-INH replacement therapies

C1-INH replacement therapy represents a dynamic therapeutic area where clinical innovation, operational resilience, and patient-centered delivery converge to define success. The ongoing evolution of product types, including advances in plasma-derived safety processes and recombinant manufacturing, has expanded therapeutic options while introducing new considerations for access and procurement. Meanwhile, shifts toward subcutaneous formulations and homecare delivery models are reshaping patient experiences and clinical workflows, prompting stakeholders to reassess training, reimbursement, and support infrastructures.

Trade policy fluctuations and regional regulatory diversity have underscored the importance of diversified sourcing, nearshoring where feasible, and proactive engagement with payers and health systems to ensure continuity of care. Segmentation insights clarify that strategic choices around product formulation, indication targeting, administration route, care setting, and distribution channel materially affect adoption patterns and service requirements. As the field matures, stakeholders that integrate robust evidence generation with resilient commercial and operational strategies will be best positioned to deliver consistent patient value and sustainable access.

In sum, thoughtful alignment of clinical differentiation, supply-chain robustness, and payer-centered value propositions will determine which programs attain durable traction in clinical practice and payer formularies, ultimately shaping the future standard of care for patients requiring C1-INH replacement therapy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. C1-INH Replacement Therapy Market, by Product Type

  • 8.1. Plasma Derived C1-INH
    • 8.1.1. Nanofiltered C1-INH
    • 8.1.2. Pasteurized C1-INH
  • 8.2. Recombinant C1-INH

9. C1-INH Replacement Therapy Market, by Indication

  • 9.1. Acute Treatment
  • 9.2. Prophylaxis
    • 9.2.1. Long Term Prophylaxis
    • 9.2.2. Short Term Prophylaxis

10. C1-INH Replacement Therapy Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Subcutaneous

11. C1-INH Replacement Therapy Market, by End User

  • 11.1. Homecare Setting
  • 11.2. Hospital
  • 11.3. Specialty Clinic

12. C1-INH Replacement Therapy Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. C1-INH Replacement Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. C1-INH Replacement Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. C1-INH Replacement Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States C1-INH Replacement Therapy Market

17. China C1-INH Replacement Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AstraZeneca PLC
  • 18.6. Biotest AG
  • 18.7. CSL Behring GmbH
  • 18.8. GlaxoSmithKline plc
  • 18.9. Grifols S.A.
  • 18.10. Kedrion S.p.A.
  • 18.11. LFB S.A.
  • 18.12. Merck & Co. Inc.
  • 18.13. Octapharma AG
  • 18.14. Pfizer Inc.
  • 18.15. Pharming Group N.V.
  • 18.16. Sanofi S.A.
  • 18.17. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL C1-INH REPLACEMENT THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY NANOFILTERED C1-INH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY NANOFILTERED C1-INH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY NANOFILTERED C1-INH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PASTEURIZED C1-INH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PASTEURIZED C1-INH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PASTEURIZED C1-INH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RECOMBINANT C1-INH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RECOMBINANT C1-INH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RECOMBINANT C1-INH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ACUTE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ACUTE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SHORT TERM PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SHORT TERM PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SHORT TERM PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOMECARE SETTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOMECARE SETTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOMECARE SETTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 134. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 136. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 158. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 166. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 168. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)